GlassScriptPhysician profile
Aaron Fischer
NPI 1659943728
$5,985.62
in general payments reported to CMS, 2019-2025
23 companies · $4,599 in 2025
The $4,599 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $208 · 2023: $90.24 · 2024: $1,088 · 2025: $4,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,818 · Travel and Lodging: $1,914 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,817.81 |
| Travel and Lodging | $1,914.32 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,481.79 | 2025 | General - Therapies, General - Pain Management, Intracept |
| Medtronic, INC. | $1,428.72 | 2024-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Saluda Medical Americas, INC. | $1,288.85 | 2024-2025 | Evoke |
| Globus Medical, INC. | $273.11 | 2025 | Senza, Vyrsa V1 |
| Vertex Pharmaceuticals Incorporated | $190.42 | 2025 | |
| Biotronik Nro, INC. | $166.25 | 2025 | Prospera |
| Nalu Medical, INC. | $159.97 | 2024 | Nalu Neurostimulation System |
| Si-Bone, INC. | $153.50 | 2025 | |
| Amgen INC. | $107.33 | 2024-2025 | Krystexxa |
| Curonix LLC | $102.97 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Merck Sharp & Dohme LLC | $93.01 | 2022-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Abbvie INC. | $86.56 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $77.51 | 2022-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $69.28 | 2022-2023 | Jardiance, Emgality |
| Glaxosmithkline, LLC. | $61.32 | 2024 | Shingrix, Bexsero, Flulaval Quadrivalent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $54.58 | 2024 | Senza |
| Sanofi-Aventis U.S. LLC | $42.85 | 2022 | |
| Tersera Therapeutics LLC | $28.15 | 2025 | Prialt |
| Sanofi Pasteur INC. | $26.30 | 2022 | |
| Hologic Sales and Service, LLC | $25.48 | 2025 | Aptima |
| Exact Sciences Corporation | $23.28 | 2023 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $22.55 | 2025 | Xtampza |
| Pfizer INC. | $21.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.